Clinical trials recruiting for Metastatic Pancreatic Ductal Adenocarcinoma
12
Recruiting trials
32
US states with sites
21
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Gemcitabine | 3 |
| Nab-paclitaxel | 3 |
| Cetuximab | 2 |
| mFOLFIRINOX | 2 |
| Azenosertib | 1 |
| BBO-10203 | 1 |
| BBO-11818 | 1 |
| BCNU | 1 |
| Balstilimab | 1 |
| Bevacizumab | 1 |
| Botensilimab | 1 |
| Cobimetinib | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 5 |
| California | 4 |
| Florida | 4 |
| Massachusetts | 3 |
| Missouri | 3 |
| Oregon | 3 |
| Texas | 3 |
| Washington | 3 |
| Arizona | 2 |
| Connecticut | 2 |
| Illinois | 2 |
| Kansas | 2 |
Top cities
New York, New York 4Boston, Massachusetts 3Houston, Texas 3Los Angeles, California 3Portland, Oregon 3Seattle, Washington 3Baltimore, Maryland 2Dallas, Texas 2Jacksonville, Florida 2La Jolla, California 2
Self-screener
Recruiting trials
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
- MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
- ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
- Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Related conditions
Trials recruiting for Metastatic Pancreatic Ductal Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Stage IV Pancreatic Cancer AJCC v8 19Pancreatic Ductal Adenocarcinoma 64Locally Advanced Pancreatic Ductal Adenocarcinoma 8Stage III Pancreatic Cancer AJCC v8 14Stage II Pancreatic Cancer AJCC v8 9Metastatic Pancreatic Cancer 26Colorectal cancer 1359Solid Tumor, Adult 38Resectable Pancreatic Ductal Adenocarcinoma 5
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Pancreatic Ductal Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.